Health Care Costs Associated with Ankylosing Spondylitis in Turkey: An Analysis from Nationwide Real-World Data

Table 3

Marginal effects calculated after generalized linear model estimation.

	Prevalent cases		Incident cases
	€	𝑃 value	€	𝑃 value
Age 18–39	−320	0.227	−1040	0.045
Age 40–64	−155	0.555	−673	0.144
Age 65+	Reference		Reference
Female	−70	0.456	−177	0.332
Region
Eastern Anatolia region	226	0.622	402	0.707
Southeastern Anatolia region	Reference		Reference
Marmara region	−203	0.549	−282	0.740
Aegean region	−204	0.481	−633	0438
Mediterranean region	−350	0.312	−513	0.534
Black Sea region	−150	0.698	−178	0.839
Central Anatolia region	48	0.890	−13	0.987
Elixhauser index ≥2	129	0.580	−96.57	0.669
Individual comorbidities
Diabetics	184	0.238	−46	0.906
Respiratory	288	0.002	168	0.428
Allergy	−187	0.336	−234	0.442
Cardiovascular	131	0.234	320	0.243
Medications
Biologics	6258	0	5518	0.000
NSAIDs	−53	0.588	−263	0.239
DMARDs	−56	0.599	101	0.653

NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs.